TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26875489

Group type: EXPERIMENTAL
Intervention: 100 μg menaquinone-7 daily for 12 weeks (Study 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 200 μg menaquinone-7 daily for 4 weeks (Study 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 100 μg menaquinone-7 daily for 4 weeks (Study 1)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0 μg menaquinone-7 daily (Study 1)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (Study 2)
Number of subjects: 180
Study: 24185214

Group type: EXPERIMENTAL
Intervention: Aussie Optimism: Positive Thinking Skills Program (AOP‐PTS)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Regular Health Education curriculum (Control)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 910
Study: 21321617

Group type: EXPERIMENTAL
Intervention: bio-glass powder and bio-glass paste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bio-glass powder
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bio-glass paste
Number of subjects: 60

Group type: COMPARATOR
Intervention: control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bio-glass powder or paste
Number of subjects: 60
Study: 19519874

Group type: EXPERIMENTAL
Intervention: Diode laser (DL) and placebo gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Placebo laser and NK10% gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo laser and placebo gel
Number of subjects: 45
Study: 17198098

Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (40 microg, 2.5 microg/mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (80 microg, 5 microg/mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (160 microg, 10 microg/mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (without epinephrine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (all groups)
Number of subjects: 120
Study: 15072808

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (up to 300 mg per day) plus counselling and support
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo plus counselling and support
Number of subjects: 493
Study: 11240972

Group type: EXPERIMENTAL
Intervention: Nefazodone and terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefazodone and loratadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loratadine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nefazodone alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefazodone with terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefazodone with loratadine
Number of subjects: 0
Study: 9505799

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% energy from fat)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medium-fat diet (41% energy from fat)
Number of subjects: 20
Study: 7663138

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg p.o.)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (20 mg p.o.)
Number of subjects: 46
Study: 2660562

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g twice per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine (150 mg before bed)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 60
Study: 31769891

Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up intervention based on the Roy Adaptation Model
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Routine care plus telephone follow-up intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 66
Study: 30824917

Group type: EXPERIMENTAL
Intervention: VHost-Classifier
Number of subjects: 1000
Study: 28146403

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 111
Study: 25724409

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (150 min per week, for 12 weeks) and diet counseling
Number of subjects: 23
Study: 22745189

Group type: EXPERIMENTAL
Intervention: Sulpiride (400 mg, selective D2 antagonist)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 23
Study: 21224867

Group type: EXPERIMENTAL
Intervention: Bilberries (BB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sea buckthorn (SB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sea buckthorn phenolic extract (SBe)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBo)
Number of subjects: 80
Study: 19104406

Group type: EXPERIMENTAL
Intervention: TAC/DAC
Number of subjects: 602

Group type: COMPARATOR
Intervention: TAC/MMF
Number of subjects: 602
Study: 16822120

Group type: EXPERIMENTAL
Intervention: Homework compliance during cognitive-behavioral therapy (CBT)
Number of subjects: 123
Study: 12643517

Group type: EXPERIMENTAL
Intervention: Coasted group (n = 157)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (n = 208)
Number of subjects: 365
Study: 10866898

Group type: EXPERIMENTAL
Intervention: REM/PRO (75 microg. kg(‐1). min(‐1))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: REM/DES (0.5 minimum alveolar anesthetic concentration)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: REM/SEVO (0.5 minimum alveolar anesthetic concentration)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopental/alfentanil/isoflurane/N(2)O (control group)
Number of subjects: 120
Study: 9069159

Group type: EXPERIMENTAL
Intervention: Trabecular BMD in women aged 55-69 years
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Trabecular texture index in women aged 70-79 years
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: I-texture in women aged 55-59 years
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Muscle area in women aged 60-69 years
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cortical BMD and muscle area in women aged 70-79 years
Number of subjects: 122
Study: 8472110

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) as the insufflation agent
Number of subjects: 142

Group type: COMPARATOR
Intervention: Air as the insufflation agent
Number of subjects: 142
Study: 2581322

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 0
Study: 31501905

Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 20
Study: 29743040

Group type: EXPERIMENTAL
Intervention: Dissonance-based intervention consisting of four group sessions three months post-surgery
Number of subjects: 259

Group type: COMPARATOR
Intervention: Usual follow-up care (Control group)
Number of subjects: 259
Study: 27191255

Group type: EXPERIMENTAL
Intervention: Maxillary canine retraction using mini-implants as anchorage for approximately 4 months with 100g of force via coil springs.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment).
Number of subjects: 24
Study: 25029424

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22583843

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (HFS) of the left atrium, n = 15
Number of subjects: 30

Group type: COMPARATOR
Intervention: No high-frequency stimulation (Control), n = 15
Number of subjects: 30
Study: 20574929

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100
Study: 18030072

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15651944

Group type: EXPERIMENTAL
Intervention: Intramuscular naloxone (2 mg)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Intranasal naloxone (2 mg)
Number of subjects: 155
Study: 12186247

Group type: EXPERIMENTAL
Intervention: Vocal music
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 47

Group type: COMPARATOR
Intervention: Natural sound (murmurings of a stream)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No music
Number of subjects: 47
Study: 10570736

Group type: EXPERIMENTAL
Intervention: Mechanical support of minute ventilation for chronic but stable diseases (e.g., old polio, quadriplegia, kyphoscoliosis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical support of minute ventilation for chronic and progressive diseases (e.g., muscular dystrophy, amyotrophic lateral sclerosis)
Number of subjects: 0
Study: 7598463

Group type: EXPERIMENTAL
Intervention: Intensive treatment of IDDM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved glycemic control in NIDDM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive treatment recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any improvement in glycemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of insulin in NIDDM patients
Number of subjects: 0
Study: 2357093

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 64

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 64
Study: 786832

Group type: EXPERIMENTAL
Intervention: Neuro-Demoplas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (antiphologistic containing high dosage of vitamin B complex and Metamizol)
Number of subjects: 0
Study: 31928505

Group type: EXPERIMENTAL
Intervention: WeChat (WC)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Specialist team (ST)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Combined WeChat and Specialist team (WC-ST)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 1400
Study: 31695350

Group type: EXPERIMENTAL
Intervention: EX+NEPA
Number of subjects: 40

Group type: COMPARATOR
Intervention: EX
Number of subjects: 40
Study: 27387522

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conservative therapy (non-ASV)
Number of subjects: 31
Study: 25289711

Group type: EXPERIMENTAL
Intervention: 3 g L-carnitine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4 g L-carnitine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 23660990

Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 72
Study: 22164964

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium enteric coated tablets (test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac sodium enteric coated tablets (reference formulation)
Number of subjects: 0
Study: 19958553

Group type: EXPERIMENTAL
Intervention: Con‐Dis device
Number of subjects: 10

Group type: COMPARATOR
Intervention: Questionnaire-based assessment (RAI and RAVA)
Number of subjects: 10
Study: 16942535

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 15557875

Group type: EXPERIMENTAL
Intervention: Levocarnitine
Number of subjects: 0
Study: 11096234

Group type: EXPERIMENTAL
Intervention: Intermittent hormonal deprivation using luteinizing hormone-releasing hormone (LHRH) analogue alone (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intermittent hormonal deprivation associated with an antiandrogen (n = 32)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intermittent hormonal deprivation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intermittent androgen suppression
Number of subjects: 43
Study: 9042671

Group type: EXPERIMENTAL
Intervention: Cuff-uroflow (CUF) technique
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 26
Study: 8354733

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 or 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 or 100 mg) + Ethanol (0.8 g/kg)
Number of subjects: 0
Study: 3564877

Group type: COMPARATOR
Intervention: Bain system at VF of 125 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bain system at VF of 100 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lack system at VF of 70 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lack system at VF of 55 ml X min‐1 X kg‐1 b.w.
Number of subjects: 34
Study: 30513923

Group type: EXPERIMENTAL
Intervention: CPO (composite supplement containing collagen peptide and ornithine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 27427811

Group type: EXPERIMENTAL
Intervention: Parenting-focused program for divorced families
Number of subjects: 240

Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 240
Study: 25026889

Group type: EXPERIMENTAL
Intervention: Personalized invitation letter
Number of subjects: 4775

Group type: EXPERIMENTAL
Intervention: Personalized invitation letter + informative leaflet
Number of subjects: 4775

Group type: EXPERIMENTAL
Intervention: Personalized invitation letter + informative leaflet + personalized appointment reminder phone call
Number of subjects: 4775

Group type: COMPARATOR
Intervention: No specific action taken (control group)
Number of subjects: 4775
Study: 23113437

Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD-ROM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20202953

Group type: EXPERIMENTAL
Intervention: 100 mg of oral indomethacin
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 18722198

Group type: EXPERIMENTAL
Intervention: Recreational soccer (n = 14)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waiting list control (n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 22
Study: 15910111

Group type: EXPERIMENTAL
Intervention: Active retinal tracker
Number of subjects: 2
Study: 14959469

Group type: EXPERIMENTAL
Intervention: Enalapril for a month
Number of subjects: 55

Group type: COMPARATOR
Intervention: Adelphan and papasol for a month (Control)
Number of subjects: 55
Study: 10703539

Group type: EXPERIMENTAL
Intervention: GADA (glutamic acid decarboxylase antibodies)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: ICA (islet cell antibodies)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Double positivity for GADA and ICA
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Follow-up of ICA-positive children
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Follow-up of GADA-positive children
Number of subjects: 614
Study: 8697549

Group type: EXPERIMENTAL
Intervention: Rocuronium continuous infusion starting at 0.6 mg.kg‐1.hr‐1, adjusted by 0.1 mg.kg‐1.hr‐1 to maintain one visible twitch of the TOF.
Number of subjects: 20
Study: 1757603

Group type: EXPERIMENTAL
Intervention: Halobetasol propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halobetasol propionate ointment
Number of subjects: 0
Study: 6761135

Group type: EXPERIMENTAL
Intervention: Neutron radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 0
Study: 31018892

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 28094434

Group type: EXPERIMENTAL
Intervention: Remifentanil plus propofol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 88
Study: 25758155

Group type: EXPERIMENTAL
Intervention: MCT + CACR
Number of subjects: 57

Group type: COMPARATOR
Intervention: CACR + control group
Number of subjects: 57
Study: 23528398

Group type: EXPERIMENTAL
Intervention: 1% emoxipine solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5% reamberin solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% mexidol solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21647846

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA (2.5% lidocaine and 2.5% prilocaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18796000

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg/IV within the first 2 weeks and at 3 months after transplantation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (glucose infusions at the same time points)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg/IV
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 16774715

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Befriending (Control in LN study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (Control in IS study)
Number of subjects: 0
Study: 14992899

Group type: EXPERIMENTAL
Intervention: Hypothermic protective solution
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 11698275

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg rabbit ATG (Thymoglobulin)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 15 mg/kg rabbit ATG
Number of subjects: 109

Group type: COMPARATOR
Intervention: No ATG
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 109
Study: 9293721

Group type: EXPERIMENTAL
Intervention: PRP-T Hib conjugate vaccine
Number of subjects: 42848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42848
Study: 8282480

Group type: EXPERIMENTAL
Intervention: Human recombinant interferon-alpha (rIFN-alpha) at a dose of 3 x 10(6) units thrice weekly for three months, followed by 1.5 x 10(6) units thrice weekly for the next three months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Human recombinant interferon-alpha (rIFN-alpha)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 21
Study: 2954221

Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthopaedists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic subgroups
Number of subjects: 0
Study: 29043861

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (no-ENBD)
Number of subjects: 160
Study: 27843803

Group type: EXPERIMENTAL
Intervention: Duligotuzumab (1100 mg IV, q2w)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m2 load, 250 mg/m2 IV, q1w)
Number of subjects: 121
Study: 25665116

Group type: EXPERIMENTAL
Intervention: FLOSEAL 5 mL
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: FLOSEAL 10 mL
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (no FLOSEAL)
Number of subjects: 157
Study: 23046438

Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs) 50 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs)
Number of subjects: 33
Study: 21966075

Group type: EXPERIMENTAL
Intervention: DXP 3 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: DXP 6 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 221
Study: 17888542

Group type: EXPERIMENTAL
Intervention: High-calorie milkshake preload
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-calorie milkshake preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study: 16702703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical actions (e.g., speak positively about treatments, provide encouragement)
Number of subjects: 0
Study: 12811019

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized ragweed pollen extract tablets
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with highest dose (3 tablets 3 times a week)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11198487

Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy (PSP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy patients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Multiple system atrophy (MSA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All groups (PSP, Healthy, MSA)
Number of subjects: 8
Study: 8649658

Group type: EXPERIMENTAL
Intervention: 1.25 mmol/l Ca dialysate
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1.75 mmol/l Ca dialysate
Number of subjects: 45
Study: 1350803

Group type: EXPERIMENTAL
Intervention: Morphine at 10 mg/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine at 30 mg/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nociceptive pain
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neuropathic pain
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mood changes
Number of subjects: 10
Study: 6209080

Group type: EXPERIMENTAL
Intervention: Lorcainide (100 mg/d by mouth, three times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30853602

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 30% of PImax, three times a week for four weeks
Number of subjects: 22
Study: 30311885

Group type: EXPERIMENTAL
Intervention: Synchronous CABG and CEA
Number of subjects: 323

Group type: COMPARATOR
Intervention: Staged CABG and CEA
Number of subjects: 323
Study: 26661888

Group type: EXPERIMENTAL
Intervention: Karate training
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fitness training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68